HemoBioTech’s core product, HemoTech™, is an oxygen-carrying bovine, hemoglobin-based (Hb) solution believed to perform in a manner similar to red blood cells, as well as provide erythropoietic and anti-inflammatory activity. >>
There is a current annual shortage of 22 million units of blood worldwide. The shortage is expected to increase as demand outstrips supply. How can this challenge be resolved?
Blood Shortage: Part One
Blood Shortage: Part Two
Blood Shortage: Part Three
Corporate Profile
Company Fact Sheet
Product Profile
CEO Profile
Click here to hear Dr. Mittemeyer speak about HemoTech>>
Lt. Gen. Bernhard Mittemeyer, M.D., Former U.S. Army Surgeon General, Professor of Urology, Department of Urology, Former Interim President and Former Dean of Texas Tech University Health Sciences Center (TTUHSC), and HemoBioTech Director
HemoBioTech is traded under HMBT.OB and investment-related information is available.>>
HemoBioTech, Inc. is supported by strong management and distinguished scientific advisors and research professionals.>>
